Navigation Links
FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
Date:7/31/2008

Pathwork Diagnostics' Gene Expression Test Is the First to Receive FDA Clearance for Diagnosis of Uncertain Tumors; Problem Affects 200,000 New

U.S. Cancer Cases Annually

SUNNYVALE, Calif., July 31 /PRNewswire/ -- Pathwork Diagnostics, Inc., a molecular diagnostics company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Pathwork(R) Tissue of Origin Test for use in determining the origin of uncertain tumors. The test analyzes a tumor's gene expression pattern to help pinpoint the source of hard-to-identify tumors and is the first test of its kind to receive FDA clearance. Up to an estimated 200,000 newly diagnosed cancer patients annually in the U.S. may have a tumor for which the site of origin is uncertain after the initial diagnostic workup.(1,2,3,4) The FDA's clearance underscores the growing role that patients' genomic information can play in helping physicians make better decisions.

"Knowing the primary tumor site with greater certainty enables more appropriate cancer treatment. The growing trend in cancer care is the use of therapies that target specific tissues and their genomic components, rather than relying on a one-size-fits-all treatment approach," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "We believe the Pathwork Tissue of Origin Test will help provide more certainty in tumor diagnosis, which will enable more patients to realize the benefits of this new era in genomics-based diagnostics." The FDA-cleared Pathwork Tissue of Origin Test will be available as an in vitro diagnostic (IVD) kit, meaning that clinical laboratories can run the test themselves. The test is currently available as a service through Pathwork's CLIA-certified laboratory.

The Pathwork Tissue of Origin Test uses a microarray to measure the expression pattern, comprising more than 1,500 genes, in the uncertain tumor and compares it to expression patterns of a panel of 15 known tumor types, representing 60 morphologies overall, to help determine the tumor's origin. In the in vitro diagnostics clinical validation study submitted to the FDA, the test demonstrated 89 percent positive agreement (akin to sensitivity) with available diagnoses and 99 percent negative agreement (akin to specificity). The study consisted of 545 metastatic, poorly differentiated and undifferentiated tumors that had been identified as one of the 15 tumor types on the panel using existing methods.(5) The test demonstrated an average 94 percent overall concordance across four laboratories in a cross-laboratory comparison study of 60 metastatic, poorly differentiated and undifferentiated tissue specimens.(6)

"Hard-to-identify tumors are a significant clinical problem," said Dr. James Abbruzzese, Professor of Medicine at M.D. Anderson Cancer Center. "They are time-consuming and frustrating for both physicians and patients. Accurately identifying a tumor's origin -- and thus knowing what kind of cancer the patient has -- is necessary for beginning standard-of-care, cancer-specific treatment per the National Comprehensive Cancer Network Clinical Practice Guidelines. Knowing the tumor's origin can also enable patients to get into -- and benefit from -- appropriate clinical trials."

Targeted cancer therapies can be effective even with metastatic tumors and are generally tumor-specific (e.g., Herceptin(R) for breast cancer), requiring identification of the primary tumor site or tissue of origin. Targeting therapy to specific tumor types can allow patients to avoid the toxicity of broader chemotherapy.

"Traditional tools used to identify tumors of uncertain origin include imaging studies, such as CT scans and MRIs, as well as a thorough pathological evaluation with immunohistochemistry and other techniques," said Federico Monzon, M.D., Director of Molecular Diagnostics of The Methodist Hospital in Houston. "However, for difficult cases the use of these complex iterative techniques can often take weeks, and in some cases they still do not definitively identify the tissue of origin. A gene expression test like the Pathwork Tissue of Origin Test provides unique information and, based on this data, it is reasonable to expect that it will improve the diagnosis of uncertain primary tumors."

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Sunnyvale, California, develops and commercializes high-value molecular diagnostics for oncology. The company delivers FDA-cleared, microarray-based tests to clinical laboratories and also provides diagnostic tests through its CLIA-certified laboratory. The company's initial tests utilize Pathwork Diagnostics' proprietary analytics and a companion Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System. The company's first test -- the Pathwork Tissue of Origin Test -- is now FDA-cleared as an in vitro diagnostic kit. A functionally equivalent version of the test is also available through Pathwork(R) Diagnostics Laboratory. The test aids in determining a tumor's origin so that standard-of-care, cancer-specific treatment can begin. For more information, please call toll-free 1.877.808.0006 or visit http://www.pathworkdx.com.

All rights reserved. Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics logo are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.

(1) Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol

Hematol. 2005;54(3):243-250.

(2) Tong KB, Murtagh KN, Hubert HB, et al. Incidence, costs of care and

mortality of Medicare beneficiaries diagnosed with cancer of unknown

primary origin. Poster presented at the annual meeting of the American

Society of Clinical Oncology; June 2-6, 2006; Atlanta, GA.

(3) Pathwork Diagnostics analysis.

(4) American Cancer Society, Cancer Facts & Figures 2008. Atlanta:

American Cancer Society; 2008.

(5) Pathwork Tissue of Origin Test User Guide (P/N 72912).

(6) Dumur CI, Lyons-Weiler M, Sciulli C, et al. J Mol Diagn.

2008;10:67-77.


'/>"/>
SOURCE Pathwork Diagnostics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids
2. FDA Clears Advanced Test for Monitoring Metastatic Colorectal Cancer
3. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
4. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
5. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
6. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
7. Study Finds Starion Instruments Tissue Welding Technology Safe and Effective in Parotidectomy Procedures
8. Knee Pain? An Exclusive Study Engineers Cartilage to Match Patients Own Tissue
9. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
10. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
11. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):